Cancer Research and Treatment

Volume 35(5); October 2003

Editorial

Does the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy Improve the Survival of Patients with Locally Advanced Nasopharyngeal Cancer?: Gwi Eon Kim; Cancer Res Treat. 2003;35(5):369-372. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.369

Abstract PDF: No abstract available.

3,415 View
18 Download

Review Article

Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer: L Chinsoo Cho, J Michael Dimaio, Randall Hughes, Phuc Nguyen, Paula Anderson, Hak Choy; Cancer Res Treat. 2003;35(5):373-382. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.373

Abstract PDF: The majority of non-small cell lung cancer patients present with locally advanced disease that may not be resectable. A single modality treatment such as thoracic radiotherapy often results in an inferior outcome when compared to combined modality treatment. Various combinations of radiotherapy, chemotherapy, and surgery have been tested in patients with locally advanced non-small-celllung cancer with promising results. The favorable results of the combined modality treatment are accompanied by a corresponding increase in treatment related morbidity. In this article, the results of the application of combined modality treatments in the management of locally advanced non-small cell lung cancer are reviewed.

3,455 View
27 Download

Original Articles

Stomach Cancer Incidence, Mortality and Survival Rate in Korean Elderly Pharmacoepidemiologic Cohort (KEPEC) in 1994~1998: Nam Kyong Choi, Kyung Eun Youn, Dae Seuk Heo, Seung Mi Lee, Yooni Kim, Byung Joo Park; Cancer Res Treat. 2003;35(5):383-390. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.383

Abstract PDF

PURPOSE
This study was conducted to estimate the incidence, mortality and survival rate of stomach cancer in elderly people in Korea. MATERIALS AND METHODS: The source population was a Korean Elderly Phamacoepidemiologic Cohort (KEPEC), who were 65 years of age or older and living in Busan metropolitan city and Gyeongsangnam province, Korea. A subcohort of 38, 443 persons without stomach cancer were identified before enrolling the KEPEC. The stomach cancer incidence cases were detected from three different sources, the medical claims database of the Korea Medical Insurance Corporation (KMIC), the Korea Central Cancer Registry (KCCR), and the Busan Cancer Registry (BCR). A hospital survey for abstracting the relevant information to confirm the final diagnosis of the potential cases from the medical claims database was conducted. A medical oncologist reviewed the data to confirm the final diagnoses and the date of onset. The mortality cases due to stomach cancer were detected from the mortality database at the National Statistical Office. The incidence rate, the survival rate and the mortality rate of stomach cancer and their 95% confidence intervals were estimated using SAS Windows ver. 8.1. RESULTS: There were 338 confirmed stomach cancer cases in the KEPEC between 1 January 1994 and 31 December 1998. The age-standardized incidence rate of stomach cancer in the Korean elderly population was estimated to be 351.4 per 100, 000 person-years in males and 122.6 per 100, 000 person-years in females. In addition, 272 stomach cancer death cases were detected in the KEPEC between 1 Jan. 1994 and 31 Dec. 1998. The age-standardized mortality rate of stomach cancer to the Korean elderly population was estimated to be 268.5 per 100, 000 person-years in males and 93.7 per 100, 000 person-years in females. The one-year survival rate was 62.1% in males and 63.0% in females, which was considered to be statistically similar. The three-year survival rate was 38.9% in males and 40.9% in females. The five-year survival rate was 34.8% in males and 34.7% in females. CONCLUSION: The age-standardized male stomach cancer incidence rate and mortality rate to the Korean population were approximately three times higher than in female. However, there was little significant difference between males and females in terms of the overall survival rates. These results may be useful for planning a health policy for preventing and managing stomach cancer in Korea.

Citations

Citations to this article as recorded by

PLCE1 Polymorphisms Are Associated With Gastric Cancer Risk: The Changes in Protein Spatial Structure May Play a Potential Role
Xi’e Hu, Jintong Jia, Zhenyu Yang, Songhao Chen, Jingyi Xue, Sensen Duan, Ping Yang, Shujia Peng, Lin Yang, Lijuan Yuan, Guoqiang Bao
Frontiers in Genetics.2021;[Epub] CrossRef
Serum microRNA-381: A Potential Marker for Early Diagnosis of Gastric Cancer
Ye Li, Huihui Sun, Jie Guan, Tingting Ji, Xinwei Wang
Yonsei Medical Journal.2019; 60(8): 720. CrossRef
Aging over 70 Years Is Not a Decisively Dismal Prognostic Factor in Gastric Cancer Surgery
Sung-Il Cho, You-Jin Jang, Jong-Han Kim, Sung-Soo Park, Seong-Heum Park, Seung-Joo Kim, Chong-Suk Kim, Young-Jae Mok
Journal of Gastric Cancer.2011; 11(4): 200. CrossRef
Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
Jin Ho Baek, Jong Gwang Kim, Sang Kyun Sohn, Dong Hwan Kim, Kyu Bo Lee, Hong Suk Song, Ki Young Kwon, Young Rok Do, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Ho Young Chung, Wansik Yu
Journal of Korean Medical Science.2005; 20(6): 966. CrossRef

4,064 View
20 Download
4 Crossref

High Dose Radiation Therapy Concurrent with Chemotherapy in Locally Advanced Nasopharynx Cancer: Min Kyu Kang, Yong Chan Ahn, Won Park, Keunchil Park, Chung Hwan Baek, Young Ik Son, Jeong Eun Lee, Young Je Park, Hee Rim Nam, Kyoung Ju Kim, Do Hoon Lim, Seung Jae Huh; Cancer Res Treat. 2003;35(5):391-399. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.391

Abstract PDF: PURPOSE
Here, our results from a prospective treatment protocol of concurrent radiochemotherapy (CRCT), which was conducted for locally advanced nasopharynx cancers, between April 1994 and May 2001, are reported. MATERIALS AND METHODS: A total of 52 consecutive eligible patients were accumulated for this protocol. The median radiation doses to the primary site, involved nodes and uninvolved neck were 72, 61.2 and 45 Gy, using a serial shrinking field technique. The boost techniques were 3-dimensional conformal radiation therapy in 45, intracavitary brachytherapy in 3 and 2-dimensional radiation therapy, with multiple small fields, in 2 patients. Two chemotherapy regimens were used: the first regimen, used in 8 patients during the earlier part of the study duration, consisted of 2 cycles of cisplatin plus 5- fluorouracil every 4 weeks, with concurrent radiation therapy, and 4 cycles with the same agents every 4 weeks, adjuvantly; the second regimen, used in 44 patients during the later part, consisted of 3 cycles of cisplatin every 3 weeks, with concurrent radiation therapy and 3 cycles of adjuvant cisplatin plus 5-fluorouracil every 3 weeks. RESULTS: The median follow-up period of the survivors was 32 months. The male to female ratio was 36/16, with a median age of 48 years. The stages, according to the new AJCC staging system (1997), were IIb in 6, III in 23, IVa in 14 and IVb in 9 patients. Fifty and 32 patients completed the planned radiation therapy and concurrent chemotherapy, respectively. Two patients died, 1 of septic shock during the CRCT and the other of malnutrition during the adjuvant chemotherapy. There were 12 failures in 11 patients: 7 locoregional recurrences, 1 within and 6 outside the radiation target volume, and 5 distant metastases. The locoregional control, disease-free survival and overall survival rates were 84.3, 78.8 and 92.8% at 3 years, respectively. CONCLUSION: High dose radiation therapy, coupled with concurrent chemotherapy, was judged a highly effective treatment for locally advanced nasopharynx cancers.

4,091 View
19 Download

Expression of Cyclooxygenase-2 and Tumor Microvessel Density in Colorectal Cancer: Seoung Wan Chae, Jin Hee Sohn, Eo Jin Kim, Eun Yoon Cho, Bong Hwa Lee; Cancer Res Treat. 2003;35(5):400-406. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.400

Abstract PDF

PURPOSE
The increased expression of cyclooxygenase (COX)-2 has been implicated in the development and progression of human cancer. This study investigated the COX-2 expression in colorectal cancer, and its relationships with tumor angiogenesis and the clinicopathological factors. MATERIALS AND METHODS: The expression of the COX-2 protein and microvessel density were evaluated, using immunohistochemical methods, in 21 normal colonic mucosa and 190 human colorectal carcinomas. Correlations between COX-2 expression and microvessel density, as well as various clinicopathological factors, were studied in colorectal carcinomas. RESULTS: The COX-2 protein expression in epithelial cells was increased in 169 of the 190 adenocarcinoma cases (88.9%), but in only 1 of the 21 (4.8%) normal mucosa cases. The COX-2 expression was significantly increased in the differentiated compared with the undifferentiated colorectal carcinomas (p<0.05), and significantly correlated with the depth of invasion and microvessel density (p<0.05). Rectal cancers had more COX-2 positive cases than the colon cancers (p<0.05). However, there were no significant differences in the tumor size and the presence of lymphatic or vascular invasion. CONCLUSION: The overexpression of cyclooxygenase-2 in colorectal carcinomas seems to play a role in the invasion and angiogenesis of the tumors, so may be a useful marker of the prognosis. The prominent expression was also demonstrated in differentiated colorectal cancers.

Citations

Citations to this article as recorded by

Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer
Kyubo Kim, Hong-Gyun Wu, Suk Won Park, Chong Jai Kim, Charn Il Park
Cancer Research and Treatment.2004; 36(3): 187. CrossRef

4,248 View
19 Download
1 Crossref

Combination Chemotherapy of Oxaliplatin and Capecitabine in Patients with Metastatic Colorectal Cancer: a Pilot Study: Myung Ju Ahn, Ho Suck Oh, Jung Hye Choi, Young Yeul Lee, In Soon Kim, Il Young Choi, Oh Young Lee, Heung Woo Lee; Cancer Res Treat. 2003;35(5):407-410. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.407

Abstract PDF

PURPOSE
To evaluate the efficacy and toxicity of oxaliplatin and capecitabine in patients with metastatic colorectal cancer. MATERIALS AND METHODS: Between December 2001 and April 2003, fourteen patients were enrolled in this study. Oxaliplatin, 80 mg/m(2), was administered intravenously on day 1, and capecitabine, 1, 250 mg/m(2) bid po (total daily dose 2, 500 mg/m(2)), was given on days 1~14 of 3 week cycles. RESULTS: The median age of the patients was 57 years (range: 41~74), and the most common sites of metastasis were liver, lung or lymph node. Of the 12 evaluable patients, the overall response rate was 41.7%, but with no complete response. The median response duration and median progression free survival of 12 patients were 42 and 24.4 weeks, respectively. The median overall survival was not reached. A median 6 (range: 1~9), and a total 80, cycles were administered to 14 patients. 80 cycles were evaluable for toxicity. The most common hematological toxicities were NCI grades I/II anemia (45%), leucopenia (33.75%) and thrombocytopenia (17.5%). The most common non-hematological toxicities were nausea/ vomiting (28.75/5%) and neurotoxicity (8.75%). Hand and foot syndrome was noted in only 3.75%. There was no life-threatening toxicity.
CONCLUSION
Oxaliplatin and oral capecitabine combination chemotherapy showed significant activity and favorable toxicity in patients with metastatic colorectal cancer. Further studies, with larger numbers of patients and long-tern follow-up will be needed.

Citations

Citations to this article as recorded by

Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
Paul Matte, Michel Ducreux
Case Reports in Oncology.2023; : 480. CrossRef
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
J H Baek, J G Kim, S B Jeon, Y S Chae, D H Kim, S K Sohn, K B Lee, Y J Choi, H J Shin, J S Chung, G J Cho, H Y Jung, W Yu
British Journal of Cancer.2006; 94(10): 1407. CrossRef

4,714 View
21 Download
2 Crossref

Associations between Depression, Anxiety, Hostility and Fighting Spirit among Cancer Patients in a Cancer Center in Korea: Joohyung Kim, Jae Kyung Roh, Jeoung Soon Yoon, Suk Jeong Lee, Dong Yeon Lee; Cancer Res Treat. 2003;35(5):411-418. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.411

Abstract PDF

PURPOSE
The aim of this study was to examine the associations between depression, anxiety, hostility and fighting spirit among patients with stomach, colorectal or breast cancer. MATERIALS AND METHODS: 223 patients, diagnosed as with stomach, colorectal or breast cancer, undergoing chemotherapy or follow up care, were the subjects of the study. The study design was cross-sectional at the time of the survey. The degrees of depression, anxiety and hostility of the patients were assessed by the SCL-90-R scores, and the fighting spirit was measured by the Mental Adjustment to Cancer (MAC) scale score. RESULTS: The scores of anxiety and hostility of the patients at younger age were higher than those at older age (p<0.01). The patients with metastasis were more depressed than those without it (p<0.01). There was a negative association between depression and fighting spirit (p<0.001). CONCLUSION: The study showed the more depressed cancer patients had lower fighting spirit score, which was known to be one of the most active psychosocial contributors in adjusting to cancer and survival.

Citations

Citations to this article as recorded by

Associations of diagnostic awareness with psychosocial symptoms and survival time in patients with advanced lung cancer
Hulya Abali, Seda Tural Onur, Yusuf Baser, Dilara Demir, Asli Bicen
The International Journal of Psychiatry in Medicine.2024;[Epub] CrossRef
Association of Depression and Survival in Patients with Cancer over 10 Years
Joohyung Kim, Suk Jeong Lee, Jae-Kyung Roh, Sang Jun Shin
Asian Oncology Nursing.2015; 15(1): 37. CrossRef

3,626 View
32 Download
2 Crossref

Expression of the Low Molecular Weight Cyclin E is Early Event in Colorectal Carcinogenesis: Young Hak Jung, Seong Hoo Choi, Dong Guk Park; Cancer Res Treat. 2003;35(5):419-424. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.419

Abstract PDF: PURPOSE
Cyclin E is essential for the transition from the G1 to S-phase of the cell cycle, and plays important roles in carcinogenesis in many cancers. Especially, low molecular weight cyclin E is overexpressed in breast cancer and its level of expression correlates well with the progression and prognosis. Although the cyclin E level is amplified, and overexpressed, in many cancers, including colorectal cancer, the role of low molecular weight cyclin E in colorectal cancer remains to be studied. Therefore, the expression of low molecular weight cyclin E in various stages of colorectal tumors was studied. MATERIALS AND METHODS: The expression of low molecular weight cyclin E was analyzed in 45 tumors, and compared with paired normal mucosa from the same patients (6 adenomas, 11 stage A, 14 stage B and 14 stage C colorectal cancers) by Western blot analysis. The expres sion of low molecular weight cyclin E was also analyzed in normal colon mucosa from 12 healthy normal controls. RESULTS: The low molecular weight cyclin E was expressed exclusively in all stages of colon tumors, but not in the normal mucosa from the same patients or in the normal controls. However, there was no correlation between tumor progression and the degree of expression of low molecular weight cyclin E. CONCLUSION: The expression of low molecular weight cyclin E is suggested to be an early event in colorectal carcinogenesis.

3,265 View
16 Download

Original Article

Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein: Eunhee Kim, Joo Hang Kim, Taeyoung Koo, Joo Hyuk Sohn, Chae Ok Yun; Cancer Res Treat. 2003;35(5):425-432. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.425

Abstract PDF

PURPOSE
Replication-competent adenoviruses (Ads) are promising new modalities for the treatment of cancer. Selective replication of a viral agent in tumor may lead to improved efficacy over non-replicating Ads due to viral multiplication, lysis of the infected cancer cell and spread to surrounding cells. In our previous studies it was shown that the E1B 55 kD-deleted Ad (YKL-1) exhibits tumor specific replication and cell lysis, but with reduced cytolytic effects compared to the wild type adenovirus (Int J Cancer 2000;88: 454-463). Thus, improving the potency of oncolytic Ads remains an important goal for cancer gene therapy. To increase the oncolytic ability of YKL-1, an adenovirus death protein (ADP) gene was reintroduced under the control of a CMV or MLP promoter at the E3 region of the YKL-1, generating an YKL-cADP and YKL-mADP, respectively.
MATERIALS AND METHODS
The in vitro cytolytic effect of ADP expressing Ads was evaluated by MTT assay, and the induction of apoptosis by ADP expressing Ads was examined by TUNEL analysis. Finally, the antitumor effect of ADP expressing Ads was demonstrated in C33A xenograft tumor model. RESULTS: The YKL-cADP exerted a markedly enhanced cytolytic effect against H460 and SK-Hep1 cancer cell lines. The TUNEL assay indicated that the ADP-mediated cytotoxicity was largely driven by apoptosis. Finally, the YKL-cADP showed a superior antitumor effect than the YKL-1 or YKL-mADP in C33A xenografts. CONCLUSION: These lines of evidence demonstrate that the YKL-cADP induces efficient cell lysis, which is critical for the addition of therapeutic value to replicating Ads in cancer gene therapy.

Citations

Citations to this article as recorded by

The Adenovirus Death Protein – a small membrane protein controls cell lysis and disease
Fanny Georgi, Urs F. Greber
FEBS Letters.2020; 594(12): 1861. CrossRef
A compendium of adenovirus genetic modifications for enhanced replication, oncolysis, and tumor immunosurveillance in cancer therapy
Aleksei A. Stepanenko, Vladimir P. Chekhonin
Gene.2018; 679: 11. CrossRef
Oncolytic viruses: adenoviruses
Julia Niemann, Florian Kühnel
Virus Genes.2017; 53(5): 700. CrossRef

3,854 View
42 Download
3 Crossref

Original Articles

Lack of Association between Epstein-Barr Virus and Epithelial Malignancies Developed after Kidney Transplantation: Jung Seon Seo, Kyeong Hee Kang, Jin Hyoung Kang, Suk Kyeong Lee; Cancer Res Treat. 2003;35(5):433-439. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.433

Abstract PDF: PURPOSE
Organ transplant recipients are at high risk of developing malignancies due to immunosuppressive regimens. Unlike post-transplant lymphoproliferative diseases (PTLDs), where Epstein-Barr virus (EBV) plays an etiological role, there are conflicting data regarding the association of EBV with post-transplant epithelial malignancies. In order to clarify the role of EBV in carcinomas that develop after solid-organ transplantation, the presence of EBV infection in the carcinomas of post-kidney transplant patients was examined. MATERIALS AND METHODS: The presence of EBV infection in skin carcinoma (PTSC), gastric carcinoma (PTGC) and urothelial carcinoma (PTUC), which developed in the patients under an immune suppression regime following kidney transplantation, was examined. Tumors from the patients without organ transplantation were also used as a comparison in the study. The study group included five nasopharyngeal carcinomas (NPCs), one Hodgkin's disease (HD), one B-cell non-Hodgkin's malignant lymphoma (NHL) and one hypopharynx (HPC) tumor. RESULTS: Immunofluorescence assay and Western blot analysis, using sera from the same patients, confirmed that all of the tested patients were previously infected with EBV. From in situ hybridization, no EBER positive cells were detected in any of the tumor tissues obtained from the three kidney transplant recipients (PTSC, PTGC and PTUC) or in the NHL and HPC tissues. In contrast, all five of the NPC and HD tissues showed strong EBER positivity. CONCLUSION: These results suggest that there is a strong association of EBV with NPC and HD as previously reported, while no such strong association of EBV was found with epithelial malignancies that developed after kidney transplantation.

3,545 View
27 Download

Clinical Implications of VEGF and p53 Expression in Squamous Cell Carcinoma of the Cervix Treated with Radiation Therapy: Jin Oh Kang, Seong Eon Hong, Dong Wook Kang; Cancer Res Treat. 2003;35(5):440-444. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.440

Abstract PDF

PURPOSE
The present study was designed to analyze the relationship between vascular endothelial growth factor (VEGF) and p53, and their impact on clinical outcome in squamous cell carcinoma of the cervix treated with radiation therapy. MATERIALS AND METHODS: This immunohistochemical study involved 23 patients with available paraffin blocks among 46 patients who were treated during the period from 1994 to 1997 in Eulji University Hospital in Korea. Anti-VEGF mouse monoclonal antibody and DO-7 anti- p53 mouse monoclonal antibody were used as the primary antibodies. Antibody binding was detected with a LSAB kit. Staining was defined as positive for VEGF and p53, when more than 10% and 5% of the tumor cells were stained out of 500 cells counted, respectively. RESULTS: FIGO stage (p=0.05) and tumor size (p=0.04) were significant prognostic factors for survival. p53 expression was present in 17 (77%) cases. There was no significant relationship between p53 staining and the clinicopathologic factors, such as FIGO stage (p=0.98), tumor size (p=0.43), lymph node status (p=0.82), parametrial invasion (p=0.96), and age (p=0.18). The five year survival rates according to the p53 expression status were 80% for the p53 negative group and 66% for the p53 positive group (p=0.58). Positive VEGF expression was observed in 11 (47%) of the total of 23 patients. Statistical evaluation of VEGF expression according to stage (p=0.36), tumor size(p=0.11), lymph node status (p=0.82), parametrial invasion (p=0.49), and age (p=0.55) revealed no significant difference in any of these parameters. The five year survival rates according to the VEGF expression status were 89% for the VEGF negative group and 41% for the VEGF positive group (p=0.07). CONCLUSION: We suggest that VEGF expression may have an effect on the prognosis of cervix cancer patients treated with radiation therapy, and further evaluation with a large sample size is warranted.

Citations

Citations to this article as recorded by

Research advances in signaling pathways related to the malignant progression of HSIL to invasive cervical cancer: A review
Huifang Wang, Chang Liu, Keer Jin, Xiang Li, Jiaxin Zheng, Danbo Wang
Biomedicine & Pharmacotherapy.2024; 180: 117483. CrossRef

3,490 View
17 Download
1 Crossref

Relationship between PTEN and Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer: Mee Sook Roh, Jae Ik Lee, Doo Kyung Yang, Soo Keol Lee, Hyuk Chan Kwon, Mi Kyoung Park, Ki Baek Hwang, Jin A Jung; Cancer Res Treat. 2003;35(5):445-450. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.445

Abstract PDF

PURPOSE
This study was performed to determine the relationship between PTEN and vascular endothelial growth factor (VEGF) expression and to assess their roles in the tumor-induced angiogenesis and tumor progression in non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded tissues, from 96 patients diagnosed with NSCLC, were evaluated for VEGF and PTEN expression using immunohistochemical methods. The results of the expression pattern of VEGF alone, or in combination with PTEN expression, were compared with clinicopathological parameters. RESULTS: VEGF expression was seen in 54 (56.3%) of the 96 NSCLCs evaluated, and was significantly correlated with histological type, and seen more frequently in adenocarcinomas compared to the other histological types (p<0.05). There were no significant associations between VEGF expression and tumor size, lymph node metastasis and stage. The microvessel density (MVD) determined by CD34 staining were significantly higher in tumors with VEGF expression (62.9+/-21.8) than those without (55.1+/-15.1). Loss of PTEN expression was seen in 33 (34.4%) of the 96 NSCLCs evaluated. VEGF expression was more frequently detected in the tumors with loss of PTEN expression (69.7%) than in those with PTEN expression (49.2%). When the combined VEGF/ PTEN phenotypes were divide into two groups; group I (VEGF-/PTEN+) and group II (VEGF-/ PTEN-, VEGF+/PTEN+, VEGF+/PTEN-), a significant correlation was also seen between the groups and the histologic types. There was a trend for the tumors in group II to show more frequent lymph node metastasis (50.0%) than those in group I (31.5%), although there was no statistical significance. The MVDs were significantly higher in group II (63.1+/-20.7) than in group I (53.4+/-17.2). CONCLUSION: These findings demonstrate an inverse correlation between the expressions of PTEN and VEGF. It is possible that PTEN may repress VEGF expression, and modulate VEGF-mediated angiogenesis, which suggests further analysis of the complex phenomenon of neo-angiogenesis in NSCLC is essential.

Citations

Citations to this article as recorded by

Molecular and biological characterization of hepatitis B virus subgenotype F1b clusters: Unraveling its role in hepatocarcinogenesis
María Mercedes Elizalde, Laura Mojsiejczuk, Micaela Speroni, Belén Bouzas, Luciana Tadey, Lilia Mammana, Rodolfo Héctor Campos, Diego Martín Flichman
Frontiers in Microbiology.2022;[Epub] CrossRef
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Do Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Tae‐You Kim
Molecular Carcinogenesis.2010; 49(4): 353. CrossRef
Phosphatase and Tensin Homolog Reconstruction and Vascular Endothelial Growth Factor Knockdown Synergistically Inhibit the Growth of Glioblastoma
Hongbo Chen, Xiaomeng Shen, Caiping Guo, Huijun Zhu, Lanzhen Zhou, Yongqiang Zhu, Huixia Wang, Yi Zheng, Laiqiang Huang
Cancer Biotherapy and Radiopharmaceuticals.2010; 25(6): 713. CrossRef

3,521 View
56 Download
3 Crossref

cDNA Microarray Analysis of Gene Expression Profiles Associated with Cervical Cancer: Joo Hee Yoon, Joon Mo Lee, Sung Eun Namkoong, Su Mi Bae, Yong Wan Kim, Sei Jun Han, Young Lae Cho, Gye Hyun Nam, Chong Kook Kim, Jeong Sun Seo, Woong Shick Ahn; Cancer Res Treat. 2003;35(5):451-459. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.451

Abstract PDF

PURPOSE
The molecular pathology of cervical cancers associated with human papillomavirus infection is presently unclear. In an effort to clarify this issue, the gene expression profiles and pathogenic cellular processes of cervical cancer lesions were investigated. MATERIALS AND METHODS: Cervical cancer biopsies were obtained from patients at the Department of Obstetrics and Gynecology, The Catholic University of Korea. The disease status was assigned according to the International Federation of Gynecology and Obstetrics. The tissue samples of 11 patients (invasive cancer stage Ib- IIIa) were investigated by a cDNA microarray of 4, 700 genes, hierarchical clustering and the Gene Ontology (GO). Total RNA from cervical cancer and non-lesional tissues were labeled with Cy5 and Cy3. The HaCaT human epithelial keratinocyte cell line was used as a negative control cell. The stages of invasive cancer were Ib to IIIb. All specimens were obtained by punch-biopsies and frozen in liquid nitrogen until required. RESULTS: 74 genes, showing more than a 2 fold difference in their expressions, were identified in at least 8 of the 11 patients. Of these genes, 33 were up-regulated and 41 were down-regulated. The gene expression profiles were classified into 345 mutually dependent function sets, resulting in 611 cellular processes according to their GO. The GO analysis showed that cervical carcinogenesis underwent complete down-regulation of cell death, protein biosynthesis and nucleic acid metabolism. The genes related to nucleic acid binding and structural molecule activity were also significantly down-regulated. In contrast, significant up-regulation was shown in the skeletal development, immune response and extracellular activity. CONCLUSION: These data are suggestive of potentially significant pathogenetic cellular processes, and showed that the down-regulated functional profiling has an important impact on the discovery of pathogenic pathways in cervical carcinogenesis. GO analysis can also overcome the complexity of the expression profiles of the cDNA microarray via a cellular process level approach. Thereby, a valuable prognostic candidate gene, with real relevance to disease-specific pathogenesis, can be found at the cellular process levels.

Citations

Citations to this article as recorded by

The Induced Expression of BPV E4 Gene in Equine Adult Dermal Fibroblast Cells as a Potential Model of Skin Sarcoid-like Neoplasia
Przemysław Podstawski, Marcin Samiec, Maria Skrzyszowska, Tomasz Szmatoła, Ewelina Semik-Gurgul, Katarzyna Ropka-Molik
International Journal of Molecular Sciences.2022; 23(4): 1970. CrossRef
Cervical cancer heterogeneity: a constant battle against viruses and drugs
Qian Sun, Liangliang Wang, Cong Zhang, Zhenya Hong, Zhiqiang Han
Biomarker Research.2022;[Epub] CrossRef
Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4
Nada M.K. Mabrouk, Dalal M. Elkaffash, Mona Abdel-Hadi, Salah-ElDin Abdelmoneim, Sameh Saad ElDeen, Gihan Gewaifel, Khaled A. Elella, Maher Osman, Nahed Baddour
Drug Target Insights.2020; 14(1): 1. CrossRef
Comparative analysis of DNA methylation patterns of equine sarcoid and healthy skin samples
E. Semik, T. Ząbek, A. Gurgul, A. Fornal, T. Szmatoła, K. Pawlina, M. Wnuk, J. Klukowska‐Rötzler, C. Koch, K. Mählmann, M. Bugno‐Poniewierska
Veterinary and Comparative Oncology.2018; 16(1): 37. CrossRef
Transcriptome analysis of equine sarcoids
E. Semik, A. Gurgul, T. Ząbek, K. Ropka‐Molik, C. Koch, K. Mählmann, M. Bugno‐Poniewierska
Veterinary and Comparative Oncology.2017; 15(4): 1370. CrossRef
INPP5E Preserves Genomic Stability through Regulation of Mitosis
Elizabeth A. Sierra Potchanant, Donna Cerabona, Zahi Abdul Sater, Ying He, Zejin Sun, Jeff Gehlhausen, Grzegorz Nalepa
Molecular and Cellular Biology.2017;[Epub] CrossRef
IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis
Yoshinori Asano, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Satoko Tatebe, Issay Kitabayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama, Rieko Ohki
Scientific Reports.2016;[Epub] CrossRef
Hypoxic regulation of MYBL1, MEST, TCF3, TCF8, GTF2B, GTF2F2 and SNAI2 genes expression in U87 glioma cells upon IRE1 inhibition
O. H. Minchenko, D. O. Tsymbal, D. O. Minchenko, O. O. Kubaychuk
The Ukrainian Biochemical Journal.2016; 88(6): 52. CrossRef
Phosphatidylinositolphosphate phosphatase activities and cancer
Simon A. Rudge, Michael J.O. Wakelam
Journal of Lipid Research.2016; 57(2): 176. CrossRef
Gene expression profiling in the human keratinocyte cell line, hacat exposed to urushiol isolated from sap of korean lacquer tree (Rhus verniciflua Stokes)
Ju Youn Park, Jae Ho Chang, Myong Jo Kim, Ju Sung Kim, Soo-Ki Kim
Molecular & Cellular Toxicology.2010; 6(1): 79. CrossRef
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Tom D. Bunney, Matilda Katan
Nature Reviews Cancer.2010; 10(5): 342. CrossRef
The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease
Lisa M. Ooms, Kristy A. Horan, Parvin Rahman, Gillian Seaton, Rajendra Gurung, Dharini S. Kethesparan, Christina A. Mitchell
Biochemical Journal.2009; 419(1): 29. CrossRef
Altered MicroRNA Expression in Cervical Carcinomas
Jeong-Won Lee, Chel Hun Choi, Jung-Joo Choi, Young-Ae Park, Seung-Jun Kim, Seung Yong Hwang, Woo Young Kim, Tae-Joong Kim, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae
Clinical Cancer Research.2008; 14(9): 2535. CrossRef
Identification of hemoglobin‐α and ‐β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer
Ahn Woong‐Shick, Park Sung‐Pil, Bae Su‐Mi, Lee Joon‐Mo, Namkoong Sung‐Eun, Nam Gye‐Hyun, Cho Young‐Lae, Choi Ho‐Sun, Jun Heung‐Jae, Kim Chong‐Kook, Kim Young‐Wan, Han Byoung‐Don, Jin Hyun‐Sun
Cancer Science.2005; 96(3): 197. CrossRef
The Differential Gene Expression Profiles between Sensitive and Resistant Breast Cancer Cells to Adriamycin by cDNA Microarray
Myung-Ju Ahn, Ki-Hwan Lee, Joon-Ik Ahn, Dong-Hyun Yu, Hye-Sook Lee, Jung-Hye Choi, Joung Soon Jang, Jong Min Bae, Yong-Sung Lee
Cancer Research and Treatment.2004; 36(1): 43. CrossRef

4,767 View
28 Download
15 Crossref

Case Report

Use of GCDFP-15 (BRST-2) as a Specific Immunocytochemical Marker for Diagnosis of Gastric Metastasis of Breast Carcinoma: Keon Woo Park, Young Hyuck Im, Jeeyun Lee, Eungho Kim, Hyuk Lee, Bong Geun Song, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Won Ki Kang, Mark H Lee, Keunchil Park; Cancer Res Treat. 2003;35(5):460-464. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.460

Abstract PDF

Metastasis of breast cancer to the stomach is relatively uncommon and typically occurs in patients with disseminated diseases. This may cause difficulty in differentiating it from primary gastric carcinoma. The correct diagnosis of the primary source is important, since the treatment and prognosis of metastatic breast cancer is quite different from those of metastatic gastric cancer. Immunohistochemical staining with GCDFP-15 (gross cystic disease fluid protein-15) can be used to differentiate primary gastric carcinoma and gastric metastasis from breast cancer. We report two cases of gastric metastasis of breast cancer by describing their clinical course, illustrating the histologic findings, and showing the results of immunohistochemical staining with GCDFP-15.

Citations

Citations to this article as recorded by

Gastrointestinal metastasis of breast cancer: Exploring the path ahead
Peng-Yue Zhao, Zhen-Ting Zhao, Song-Yan Li, Fiona Simpson, Xiao-Hui Du
Medicine Plus.2024; 1(4): 100055. CrossRef
Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer
Natalia Sauer, Igor Matkowski, Grażyna Bodalska, Marek Murawski, Piotr Dzięgiel, Jacek Calik
Cells.2023; 12(18): 2252. CrossRef
Gastric Metastasis from Breast Cancer
So Yoon Yoon, Ki-Nam Shim
The Korean Journal of Gastroenterology.2013; 61(1): 54. CrossRef
Colon Obstruction due to Colonic Metastasis of a Breast Carcinoma
Do Hyoung Kim, In Kyu Lee, Chang Hyun Oh, Yoon Suk Lee, Jong Kyung Park, Woo Chan Park, Hae Myung Jeon, Jae Ho Byun, Gyeoung-Sin Park, Suk Kyun Chang
Journal of the Korean Society of Coloproctology.2008; 24(2): 144. CrossRef

3,782 View
27 Download
4 Crossref

First
Prev
Page of 1
Next
Last

Previous issues